INTRODUCTION
target of Chga and its bioactive peptides released from other tissues; and 2) the liver is central in 117 regulation of intermediary metabolic and glucose homeostatic aspects of the metabolic 118 syndrome. Genome-wide, transcriptome profiling in the adrenal gland and liver, with subsequent 119 transcriptional regulatory network prediction, was used to predict changes in biochemical and 120 physiological systems, with the overall objective being deeper understanding of the mechanistic 121 link between the Chga locus and metabolic syndrome traits in an intact, living organism. 122 123 124 125 determined by Affymetrix GeneChips (5, 6) . 158
159

Microarray data analysis 160
Statistical analysis of the microarray data was performed using a Bayesian statistical 161 method known as variance-modeled posterior inference with regional exponentials 162 (VAMPIRE)(9). Probe sets were considered significantly differentially expressed at p<0.05 to 163 minimize false negatives and gain a broad perspective on transcriptional and biochemical 164 systems perturbed in the Chga knockout mouse. Two functional clustering methods, 165
GenMAPP (20) HOMA insulin resistance index. Data was analyzed with a Student's t-test or ANOVA followed by 190 pairwise comparisons corrected for multiple comparisons (Bonferroni) . 191
192
Cholesterol assays 193
Both adrenal glands and a small portion of the liver (~200 mg) were harvested from Chga 194 knockout (n=6) and wild-type control mice (n=6) and homogenized in 400 μL (for adrenal gland) 195 or 1 mL (for liver) 10 mM HEPES buffer, pH 7, and stored on ice. Homogenized tissues were 196 subjected to three rounds of centrifugation at 14,000 rpm for 10 minutes at 4˚C, in a tabletop 197 centrifuge, discarding the pellet after each round. Total cholesterol in plasma, adrenal gland, and 198 liver was measured using an enzymatic, colorimetric kit (Roche, US#450061) and the COBAS 199 MIRA Plus Chemistry Analyzer (Roche, Basel, Switzerland) . Liver cholesterol measurements 200 were normalized by wet tissue mass (g). Adrenal gland cholesterol measurements were 201 normalized by total protein (mg), as determined by a colorimetric assay based on the Bradford 202 method (Bio-Rad, Hercules, CA; #500-0006). Data was analyzed with a Student's t-test. 203
204
Triglyceride assays 205
Plasma, both adrenal glands, and a small portion of the liver were harvested from Chga 206 knockout (n=8 plasma; n=6 adrenal gland, n=7 liver) and wild-type (n=8 plasma; n=6 adrenal 207 gland; n=6 liver) control mice. Triglycerides were measured in plasma or tissue lysate using an 208 enzymatic, colorimetric kit (Wako Diagnostics, Richmond, VA) and the COBAS MIRA Plus 209
Chemistry Analyzer (Roche, Basel, Switzerland). Liver triglyceride measurements were 210 normalized by wet tissue mass (g). Adrenal gland triglyceride measurements were normalized 211 by total protein (mg), as determined by a colorimetric assay based on the Bradford method Rad, Hercules, CA; #500-0006). Data was analyzed with a Student's t-test. 213
214
Computational transcription factor interaction network prediction 215
We used the PAINT (Promoter Analysis and Interaction Network Toolset, v3.5) algorithm 216 (http://www.dbi.tju.edu/dbi/tools/paint)(28) to identify the set of transcription factors 217 predicted to regulate expression of the genes contained in the DAVID and GenMAPP functional 218 clusters. In brief, PAINT analyzes a given set of promoter sequences for the presence of 219 transcription factor binding sites. The algorithm utilizes the transcription factor binding 220 matrices in the TRANSFAC database to produce a gene/transcription factor interaction matrix 221 that represents a candidate transcriptional regulatory network. Functional cluster analysis (DAVID) in the adrenal gland revealed one statistically 250 significant functional cluster of genes involved in adrenal sterol/steroid/lipid metabolism 251 (p=0.00134; Table 2 ). Pathway analysis (GenMAPP) of adrenal gene expression uncovered that 252 the cholesterol biosynthesis pathway was globally underexpressed in the Chga knockout mouse 253 (93.3% of all genes are underexpressed; 14 underexpressed genes/15 total genes) (pathway 254 significance: p<0.001; Figure 2 ). HMG-CoA reductase (Hmgcr), the rate-limiting enzyme in 255 cholesterol biosynthesis, was underexpressed 2.60-fold in the Chga knockout mouse. 256
Functional cluster analysis (DAVID) of hepatic gene expression identified two statistically 257 significant clusters of genes involved in sterol/steroid/lipid metabolism (cluster-1 p-258 value=2.96E-10; cluster-2 p-value=4.3E-5; Table 3 ). Pathway analysis (GenMAPP) revealed a 259 pattern of global overexpression of the hepatic cholesterol biosynthesis pathway in the Chga 260 knockout mouse (73.3% of all genes are underexpressed; 11 underexpressed genes/15 total 261 genes) (pathway significance: p<0.001; Figure 3) Chga knockout mice (145.3 ± 14.6 mg/dL) ( Figure 4A ). Plasma insulin concentration was 268 reduced 4.5-fold in Chga knockout mice (0.44 ± 0.09 ng/mL) compared to wild-type mice (1.96 ± 269 0.12 ng/mL) (p<0.0001; Figure 4B ). The HOMA (homeostasis model assessment) index of insulin 270 resistance in Chga knockout mice (1.7 ± 0.3) was 3.8-fold lower than the HOMA index in wild-271 type mice (6.4 ± 0.7) (p<0.002; Figure 4C ). 272
Acute treatment (30 minutes) with exogenous pancreastatin peptide (PST) had no effect on 273 the HOMA insulin-resistance index in wild-type mice (6.4 ± 0.7 without PST vs. 5.6 ± 1.3 after 274 PST) but resulted in a 2.5-fold increase in HOMA in Chga knockout mice (1.7 ± 0.3 without PST vs. 275 4.2 ± 0.9 after PST) (p=0.04; Figure 5 ). There was no statistical difference between wild-type 276 mice without pancreastatin treatment (6.4 ± 0.7) and Chga knockout mice after pancreastatin 277 treatment (4.2 ± 0.9) ( Figure 5) . 278
There was no difference in plasma total cholesterol between Chga knockout (99.0 ± 4.4 279 mg/dL) and wild-type mice (94.3 ± 6.8 mg/dL) ( Figure 6A ). Measurement of adrenal total 280 cholesterol levels revealed a 1.8-fold reduction of cholesterol levels in Chga knockout adrenal 281 gland (0.41 ± 0.05 mg/mg tissue protein) compared to wild-type adrenal gland (0.72 ± 0.12 282 mg/mg tissue protein) (p=0.039; Figure 6B ). Measurement of hepatic total cholesterol levels 283 revealed a 1.8-fold elevation in Chga knockout liver (6.0 ± 0.7 mg/g wet tissue mass) compared 284 to wild-type liver (3.4 ± 0.6 mg/g wet tissue mass) (p=0.018; Figure 6C ). 285
The plasma concentration of triglycerides was reduced 1.3-fold in Chga knockout mice 286 (74.3 ± 5.1 mg/dL) compared to wild-type mice (95.9 ± 7.2 mg/dL) (p<0.05; Figure 7A) . Adrenal 287 triglyceride level was reduced 3.9-fold in Chga knockout mice (2.5 ± 0.3 mg/mg tissue protein) 288 compared to wild-type mice (9.7 ± 1.9 mg/mg tissue protein) (p=0.004; Figure 7B ). No difference 289 in hepatic triglyceride level was detected between Chga knockout (236.5 ± 15.9 mg/g wet tissue 290 mass) and wild-type mice (233.1 ± 22.1 mg/g wet tissue mass) ( Figure 7C ). 291
292
Transcriptional regulatory networks 293 PAINT analysis of the DAVID and GenMAPP functional clusters produced one candidate 294 transcriptional regulatory network for each gene cluster. The insulin signaling pathway in the 295 adrenal gland (Figure 1 ) was predicted to be regulated by a network of 15 transcription factors, 296 5 of which were differentially expressed in Chga knockout adrenal glands: Egr1 (overexpressed 297 +3.89-fold), Myc (underexpressed -1.39-fold), Nfia (underexpressed -1.54-fold), Nfic 298 (overexpressed +1.24-fold), and Tcf3 (overexpressed +1.76-fold) ( Table 4) . 299
PAINT identified two partially-overlapping transcriptional networks regulating the 300 adrenal (Table 2 ) and hepatic (Table 3 ) DAVID lipid/sterol/steroid functional clusters (Table 5) . Figure 4A ), yet the concentration of plasma insulin was 4.5-fold less than the 366 concentration in wild-type mice (p<0.0001; Figure 4B ). The Chga knockout mouse thus requires 367 only ~20% of the insulin that wild-type mice need in order to maintain normal blood glucose 368 levels, an indication that chromogranin A can regulate sensitivity to insulin and that the Chga 369 knockout mouse is hypersensitive to insulin. The 3.8-fold reduction of the HOMA index (a 370 standard metric of insulin resistance(29)) (p<0.002) Figure 4C ), provides additional evidence 371 that Chga knockout mice are more sensitive to insulin than wild-type mice. 372
Since plasma triglyceride concentration is positively and strongly correlated with insulin 373 sensitivity/resistance as part of the metabolic syndrome(8, 15), the 1.3-fold reduction of plasma 374 triglyceride concentration (p<0.05; Figure 7A ) is consistent with an insulin sensitivity phenotype 375 in the Chga knockout mouse. Interestingly, the liver, which is the main source of triglycerides in 376 the body, showed no difference in triglyceride levels between Chga knockout and wild-type mice 377 ( Figure 7C ), suggesting that other tissues (e.g., adipose) are responsible for the reduction in 378 plasma triglyceride concentration. The extent to which the 3.9-fold reduction of triglycerides in 379 the Chga knockout adrenal gland (p=0.004; Figure 7B ) contributed to the decreased plasma 380 triglyceride concentration is uncertain. 381
Additional experiments, such as insulin tolerance tests (ITT) and glucose tolerance tests 382 (GTT), can probe the kinetic and temporal characteristics of increased insulin sensitivity in the 383
Chga knockout mouse and perhaps identify cell-and tissue-specific mechanisms whereby 384 chromogranin A and/or its proteolytically-derived peptides regulate glucose homeostasis and 385 influence insulin sensitivity. 386
The notion that chromogranin A can regulate insulin sensitivity is not new; however, these 387 results are the first to show a direct effect of genetic variation at the Chga locus (i.e., gene 388 knockout) on insulin sensitivity in an intact, living organism. The most likely mechanism 389 whereby chromogranin A can regulate insulin sensitivity is through its proteolytically-derived 390 peptide fragment, pancreastatin (human CHGA 250-301 -amide), the so-called "dysglycemic" 391 peptide. A diverse set of potentially dysglycemic actions of pancreastatin has been reported in 392 isolated cells and tissues (23, 30) , including inhibition of glucose-stimulated insulin release from 393 pancreatic islet beta cells (24); inhibition of glucose uptake by adipocytes and hepatocytes (7); 394 and inhibition of insulin signaling in adipocytes(23). Dysglycemic effects have also been reported 395 in vivo during intramesenteric vein injection of pancreastatin in the rat (21, 22) , and during 396 infusion of the peptide into the brachial artery while studying skeletal muscle glucose uptake in 397 the human forearm model(1). Thus, lack of pancreastatin is likely to be the major factor 398 responsible for enhanced insulin sensitivity in the Chga knockout mouse, though additional 399 experiments are required to identify involvement of specific cell and tissue types and to 400 elucidate cellular mechanisms of pancreastatin action; for example, identification of a 401 pancreastatin receptor has remained elusive. 402
Mahapatra et al. previously demonstrated that administration of exogenous catestatin 403 peptide (an inhibitor of catecholamine secretion) normalized hypertension (elevated blood 404 pressure) in the Chga knockout mouse(13). With a similar rationale, we administered exogenous 405 pancreastatin peptide (a hormone with "dysglycemic" effects) to Chga knockout mice and were 406 able to restore the state of insulin sensitivity to near-normal levels ( Figure 5 ). Pancreastatin 407 treatment did not completely normalize insulin sensitivity to wild-type levels (though there was 408 no statistical difference in HOMA between wild-type mice without pancreastatin treatment and 409
Chga knockout mice after pancreastatin treatment). It is possible that the intraperitoneal (IP) 410 dose of pancreastatin resulted in a circulating concentration below normal physiological level, 411
and/or that a longer treatment period (>30 minutes) is required to achieve complete 412 normalization. More intriguingly, it is possible that other functional peptides derived from 413 chromogranin A (e.g., catestatin, vasostatin) without a currently known role in glucose 414 homeostasis can also regulate insulin sensitivity. It is also important to note that exogenous 415 pancreastatin had no effect in wild-type mice, an indication that the normal, physiological 416 concentration of endogenous pancreastatin is near or at the level required to saturate the 417 system. Though the genomic and non-genomic mechanisms of action by pancreastatin are 418 incompletely understood, our gene expression pathway mapping (Figures 1-3 (Table 2 ). Pathway analysis (GenMAPP) revealed that the adrenal cholesterol 424 biosynthesis pathway is globally underexpressed in the Chga knockout mouse (p<0.001, Figure  425 2), including 2.60-fold underexpression of HMG-CoA reductase, the rate-limiting enzyme in the 426 pathway. In contrast, functional cluster (DAVID) and pathway (GenMAPP) analysis of hepatic 427 gene expression identified functional clusters of differentially expressed genes involved in 428 sterol/steroid/lipid metabolism (Table 3) 
Experimental confirmation of decreased adrenal and increased hepatic cholesterol 435
We confirmed that cholesterol levels were indeed altered in the adrenal gland and liver in 436 the direction predicted by differential gene expression patterns: adrenal cholesterol was 437 decreased 1.8-fold in Chga knockout mice (p=0.039; Figure 6B ); hepatic cholesterol was 438 increased 1.8-fold in Chga knockout mice (p=0.018; Figure 6C The adrenal insulin signaling pathway transcriptional regulatory network contained 15 478 transcription factors predicted to control the expression of the 29 differentially expressed genes 479 in the pathway (Table 4) . We detected a difference in mRNA abundance for 5 of the 15 480 transcription factors in the network (Egr1, +3.89-fold; Myc -1.39-fold; Nfia -1.54-fold; Nfic, 481 +1.24-fold; Tcf3 +1.76-fold), and the differential expression of these 5 transcription factors could 482 provide a mechanistic link between chromogranin A gene knockout and altered insulin 483 sensitivity. Since the target receptor and mechanism of action of the "dysglycemic" pancreastatin 484 fragment derived from chromogranin A remain largely unknown, further investigation of Egr1, 485
Myc, Nfia, Nfic, and Tcf3 could provide novel insights into pancreastatin signaling. 486
The adrenal lipid/sterol/steroid functional cluster (Table 2 ) transcriptional regulatory 487 network contained 17 transcription factors while the hepatic lipid/sterol/steroid functional 488 cluster (Table 3 ) transcriptional regulatory network contained 29 transcription factors (Table 5) . 489
The disparity in the number of transcription factors between the adrenal gland and liver 490 highlights the quite different responses of lipid metabolism in each tissue to chromogranin A 491 depletion. In fact, just 7 transcription factors showed the same direction of response (i.e., no 492 change, overexpression, underexpression) in both the adrenal gland and liver. 493
The cholesterol biosynthesis pathway (Figure 2, Figure 3 ) transcriptional regulatory 494 network contained 26 transcription factors (Table 6 ). We observed a difference in the direction 495 of mRNA differential expression (i.e., no change, overexpressed, or underexpressed) between the 496 adrenal gland and liver for 10 of the 26 transcription factors: Atf2, Jun, Cebpd, Dbp, E2f1, E2f5, 497 Hivep2, Nfya, Nfyb, and Pax6. The tissue-specific changes in direction of differential expression 498 for these 10 transcription factors could contribute to the dramatic differences in gene expression 499 patterns in the cholesterol biosynthesis pathway between the adrenal gland (global 500 underexpression) and liver (global overexpression), and the differences in cholesterol level in the 501 adrenal gland (decreased 1.8-fold) and liver (increased 1.8-fold). These 10 transcription factors 502 provide avenues for additional investigation into the poorly understood link between 503 chromogranin A, adrenal and hepatic cholesterol, and insulin sensitivity. 504 505 506 507
CONCLUSIONS AND PERSPECTIVES 508
Genome-wide transcriptome profiling in the Chga knockout mouse uncovered patterns of 509 adrenal and hepatic gene expression suggesting changes in tissue-specific and whole body 510 biochemical and physiological systems. Prediction of increased organismal insulin sensitivity 511 was confirmed with glucose, insulin, and HOMA-IR index measurements, while tissue-specific 512 changes in cholesterol biosynthesis were verified with tissue cholesterol assays. These 513 microarray studies demonstrate the utility of transcriptome profiling in predicting changes in 514 biochemical and physiological systems, which can then be verified experimentally. The effect of 515 chromogranin A and its pancreastatin peptide fragment on insulin sensitivity has previously 516 been documented; however, our experiments demonstrate, for the first time, that genetic 517 variation in the Chga locus directly impacts insulin sensitivity in an intact, living organism. 518
Striking and directionally opposite differences in gene expression patterns in adrenal and 519 hepatic cholesterol biosynthesis were identified and highlight a novel and poorly understood 520 relationship between chromogranin A, cholesterol, and insulin sensitivity. Transcriptional 521 regulatory network prediction identified sets of transcription factors that may provide insight 522
into the yet unexplored mechanistic links between chromogranin A, cholesterol, and insulin 523 sensitivity, and yield additional avenues for investigation. Finally, the Chga knockout mouse may 524 provide a valuable model for studying the relationships among disease phenotypes of the 525 metabolic syndrome ( Figure 8) Adrenal expression patterns of genes involved in insulin signaling and trans-plasma 639 membrane glucose transport were mapped onto a biochemical pathway diagram using 640
GenMAPP. The overall pattern of expression, specifically, the overexpression of the insulin 641 receptor substrates (Irs2, Irs3, Gab1, Shc1) and primary glucose transporter (Glut4; Slc2a4), 642
suggests enhanced insulin signaling and glucose transport in the Chga knockout mouse adrenal 643 gland. Genes overexpressed in the Chga knockout are colored red, genes underexpressed in the 644
Chga knockout are colored blue, genes lacking a statistically significant change are colored gray, 645
and genes without expression data (i.e. the gene lacked a probe on the microarray) are shown in 646 white. Numbers adjacent to genes indicate the fold-change of differential expression. A positive 647 number indicates a gene that is overexpressed in the knockout (Chga KO mean signal/wild-type 648 mean signal), and a negative number refers to a gene that is underexpressed in the knockout (-649 wild-type mean signal/Chga KO mean signal PAINT analysis of the GenMAPP-derived cholesterol biosynthesis pathway identified a set of 26 873 transcription factors in the transcriptional regulatory network. Column 1 lists the standard 874 transcription factor gene symbol and the TRANSFAC binding matrix to which the transcription 875 factor binds. A "/" symbol indicates a transcription factor heterodimer. Column 2 lists the fold-876 change for the transcription factors in the adrenal microarray experiments. Column 3 lists the 877 fold-change for the transcription factors in the hepatic microarray experiments. Positive fold 878 change (+) indicates statistically significant overexpression in Chga knockout (Chga KO mean 879 signal/wild-type mean signal); negative fold-change (-) indicates statistically significant 880 underexpression in Chga knockout (-wild-type mean signal/Chga KO mean signal); "no data" 881 indicates lack of a probe for the transcription factor on the microarray; "no change" indicates 882 lack of a statistically significant fold-change on the microarray. 
